← All trials
NCT05306548
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 8, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2025
- First posted
- Apr 1, 2022
- Last posted
- Aug 16, 2022
- Enrollment
- 258
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Diakonhjemmet HospitalLead sponsor
- Diakonhjemmet HospitalOverall official - principal investigator
- Diakonhjemmet HospitalReponsible party - principal investigator
- Martina Hansen's HospitalCollaborator
- University of OsloCollaborator
- South-Eastern Norway Regional Health AuthorityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.